Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Nanocarrier drug resistant tumor interactions: novel approaches to fight drug resistance in cancer

A. Benko, D. Medina-Cruz, A. Vernet-Crua, CP. O'Connell, M. Świętek, H. Barabadi, M. Saravanan, TJ. Webster

. 2021 ; 4 (2) : 264-297. [pub] 20210619

Language English Country United States

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc22017630

Cancer is one of the biggest healthcare concerns in our century, a disease whose treatment has become even more difficult following reports of drug-resistant tumors. When this happens, chemotherapy treatments fail or decrease in efficiency, leading to catastrophic consequences to the patient. This discovery, along with the fact that drug resistance limits the efficacy of current treatments, has led to a new wave of discovery for new methods of treatment. The use of nanomedicine has been widely studied in current years as a way to effectively fight drug resistance in cancer. Research in the area of cancer nanotechnology over the past decades has led to tremendous advancement in the synthesis of tailored nanoparticles with targeting ligands that can successfully attach to chemotherapy-resistant cancer by preferentially accumulating within the tumor region through means of active and passive targeting. Consequently, these approaches can reduce the off-target accumulation of their payload and lead to reduced cytotoxicity and better targeting. This review explores some categories of nanocarriers that have been used in the treatment of drug-resistant cancers, including polymeric, viral, lipid-based, metal-based, carbon-based, and magnetic nanocarriers, opening the door for an exciting field of discovery that holds tremendous promise in the treatment of these tumors.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22017630
003      
CZ-PrNML
005      
20220720100311.0
007      
ta
008      
220718s2021 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.20517/cdr.2020.81 $2 doi
035    __
$a (PubMed)35582024
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Benko, Aleksandra $u AGH University of Science and Technology, Faculty of Materials Science and Ceramics, Krakow 30059, Poland $u These authors contributed equally to this work
245    10
$a Nanocarrier drug resistant tumor interactions: novel approaches to fight drug resistance in cancer / $c A. Benko, D. Medina-Cruz, A. Vernet-Crua, CP. O'Connell, M. Świętek, H. Barabadi, M. Saravanan, TJ. Webster
520    9_
$a Cancer is one of the biggest healthcare concerns in our century, a disease whose treatment has become even more difficult following reports of drug-resistant tumors. When this happens, chemotherapy treatments fail or decrease in efficiency, leading to catastrophic consequences to the patient. This discovery, along with the fact that drug resistance limits the efficacy of current treatments, has led to a new wave of discovery for new methods of treatment. The use of nanomedicine has been widely studied in current years as a way to effectively fight drug resistance in cancer. Research in the area of cancer nanotechnology over the past decades has led to tremendous advancement in the synthesis of tailored nanoparticles with targeting ligands that can successfully attach to chemotherapy-resistant cancer by preferentially accumulating within the tumor region through means of active and passive targeting. Consequently, these approaches can reduce the off-target accumulation of their payload and lead to reduced cytotoxicity and better targeting. This review explores some categories of nanocarriers that have been used in the treatment of drug-resistant cancers, including polymeric, viral, lipid-based, metal-based, carbon-based, and magnetic nanocarriers, opening the door for an exciting field of discovery that holds tremendous promise in the treatment of these tumors.
655    _2
$a časopisecké články $7 D016428
700    1_
$a Medina-Cruz, David $u Department of Chemical Engineering, Northeastern University, Boston, MA 02115, USA $u These authors contributed equally to this work
700    1_
$a Vernet-Crua, Ada $u Department of Chemical Engineering, Northeastern University, Boston, MA 02115, USA
700    1_
$a O'Connell, Catherine P $u Department of Chemical Engineering, Northeastern University, Boston, MA 02115, USA
700    1_
$a Świętek, Małgorzata $u Institute of Macromolecular Chemistry, Czech Academy of Sciences, Prague 16206, Czech Republic
700    1_
$a Barabadi, Hamed $u Department of Pharmaceutical Biotechnology, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran 19919-53381, Iran
700    1_
$a Saravanan, Muthupandian $u Department of Medical Microbiology and Immunology, Division of Biomedical Sciences, School of Medicine, College of Health Sciences, Mekelle University, Mekelle 231, Ethiopia
700    1_
$a Webster, Thomas J $u Department of Chemical Engineering, Northeastern University, Boston, MA 02115, USA
773    0_
$w MED00209371 $t Cancer drug resistance (Alhambra, Calif.) $x 2578-532X $g Roč. 4, č. 2 (2021), s. 264-297
856    41
$u https://pubmed.ncbi.nlm.nih.gov/35582024 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20220718 $b ABA008
991    __
$a 20220720100307 $b ABA008
999    __
$a ind $b bmc $g 1816676 $s 1168872
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 4 $c 2 $d 264-297 $e 20210619 $i 2578-532X $m Cancer drug resistance $n Cancer Drug Resist $x MED00209371
LZP    __
$a Pubmed-20220718

Find record

Citation metrics

Archiving options